Cara Therapeutics | CARA - Net Income


Cara Therapeutics reported $-6.8M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Cassava Sciences USD -8.6M 1.73M Jun/2026
Chugai Pharma JPY 143.55B 27.22B Sep/2026
Cipla INR 8.78B 884.9M Sep/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.01M 663K Jun/2026
CSL USD 401M 96.5M Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
J&J USD 210M 5.32B Sep/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Pacira USD 325.3M 320.65M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
RedHill Biopharma USD -1.54M 0 Jun/2024
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024